サマリー

経皮吸収型ドラッグデリバリーシステムの世界市場規模は、2020年に52,476.5百万ドルとなり、2021年から2030年にかけてCAGR4.9%を記録し、2030年には87,322.4百万ドルに達すると予測されています。経皮吸収型製剤は、患者の皮膚を通して有効量の薬物を送達するように設計された剤形です。経皮吸収型製剤に使用される粘着剤は、製品の安全性、効率性、品質を左右するものです。
経皮吸収型製剤は、血液中の薬物濃度を長時間にわたって適切に維持することができます。また、胃腸障害などの全身性の副作用を軽減することができます。
心臓病、糖尿病、関節炎などの慢性疾患を患う患者の数は、ライフスタイルの変化やストレスの多い労働環境のために著しく増加しています。さらに、世界的に老年人口も増加傾向にあります。これらの要因は、市場の成長にプラスの影響を与えます。しかし、経皮吸収型製剤の使用による副作用は、市場の成長を抑制する可能性があります。技術の進歩により、経皮吸収型製剤はさまざまな薬物の送達に使用できるようになりました。
経皮吸収型製剤市場は、送達のタイプ、アプリケーション、地域によって区分されます。デリバリーのタイプによって、市場はパッシブ型とアクティブ型に分類されます。用途別では、鎮痛剤、ホルモン補充療法、高血圧症、乗り物酔い、禁煙、その他に分類されます。地域別では、北米、欧州、アジア太平洋地域、LAMEAで分析されています。
世界市場で活動する主要なプレーヤーは、市場でのアウトリーチを強化し、市場の厳しい競争を維持するために、製品の打ち上げなどの主要な戦略を採用している
競合分析
本レポートで紹介する主な市場参加者は、Altaris、Bayer AG、Boehringer Ingelheim GmbH、Endo International plc、GlaxoSmithKline plc、Hisamitsu Pharmaceutical Co. Johnson & Johnson、Novartis AG、Purdue Pharma L.P. and Viatris Inc.です。

ステークホルダーにとっての主なメリット
本レポートでは、経皮吸収型製剤市場の現在および新興のトレンドとダイナミクスについて広範な分析を提供しています。
2020年から2030年までの主要な市場セグメントの市場推定を構築し、詳細な市場分析を実施します。
経皮ドラッグデリバリーシステム市場の広範な分析は、主要製品のポジショニングと市場フレームワーク内の上位競合企業のモニタリングに従うことで実施されます。
全地域の包括的な分析は、優勢な機会を決定するために提供されます。
2021年から2030年までの経皮ドラッグデリバリーシステムの世界市場予測分析が含まれています。
経皮薬物送達システム市場内の主要な市場プレイヤーをプロファイリングし、その戦略を徹底的に分析することで、経皮薬物送達システム業界の競争展望を理解することができます。

ページTOPに戻る

目次

CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO Perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter’s five forces analysis
3.4.Top player positioning
3.5.Market dynamics
3.5.1.Drivers
3.5.2.Restraints
3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market
CHAPTER 4: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY TYPE OF DELIVERY SYSTEM
4.1 Overview
4.1.1 Market size and forecast
4.2 Passive
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market analysis by country
4.3 Active
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market analysis by country
CHAPTER 5: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY APPLICATION
5.1 Overview
5.1.1 Market size and forecast
5.2 Analgesics
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market analysis by country
5.3 Hormone Replacement Therapies
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market analysis by country
5.4 Hypertension
5.4.1 Key market trends, growth factors and opportunities
5.4.2 Market size and forecast, by region
5.4.3 Market analysis by country
5.5 Motion Sickness
5.5.1 Key market trends, growth factors and opportunities
5.5.2 Market size and forecast, by region
5.5.3 Market analysis by country
5.6 Smoking Cessation
5.6.1 Key market trends, growth factors and opportunities
5.6.2 Market size and forecast, by region
5.6.3 Market analysis by country
5.7 Others
5.7.1 Key market trends, growth factors and opportunities
5.7.2 Market size and forecast, by region
5.7.3 Market analysis by country
CHAPTER 6: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY REGION
6.1 Overview
6.1.1 Market size and forecast
6.2 Asia-Pacific
6.2.1 Key trends and opportunities
6.2.2 Asia-Pacific Market size and forecast, by Type Of Delivery System
6.2.3 Asia-Pacific Market size and forecast, by Application
6.2.4 Asia-Pacific Market size and forecast, by country
6.2.4.1 Japan
6.2.4.1.1 Market size and forecast, by Type Of Delivery System
6.2.4.1.2 Market size and forecast, by Application
6.2.4.2 China
6.2.4.2.1 Market size and forecast, by Type Of Delivery System
6.2.4.2.2 Market size and forecast, by Application
6.2.4.3 India
6.2.4.3.1 Market size and forecast, by Type Of Delivery System
6.2.4.3.2 Market size and forecast, by Application
6.2.4.4 Australia
6.2.4.4.1 Market size and forecast, by Type Of Delivery System
6.2.4.4.2 Market size and forecast, by Application
6.2.4.5 South Korea
6.2.4.5.1 Market size and forecast, by Type Of Delivery System
6.2.4.5.2 Market size and forecast, by Application
6.2.4.6 Rest of Asia-Pacific
6.2.4.6.1 Market size and forecast, by Type Of Delivery System
6.2.4.6.2 Market size and forecast, by Application
6.3 LAMEA
6.3.1 Key trends and opportunities
6.3.2 LAMEA Market size and forecast, by Type Of Delivery System
6.3.3 LAMEA Market size and forecast, by Application
6.3.4 LAMEA Market size and forecast, by country
6.3.4.1 Brazil
6.3.4.1.1 Market size and forecast, by Type Of Delivery System
6.3.4.1.2 Market size and forecast, by Application
6.3.4.2 Saudi Arabia
6.3.4.2.1 Market size and forecast, by Type Of Delivery System
6.3.4.2.2 Market size and forecast, by Application
6.3.4.3 South Africa
6.3.4.3.1 Market size and forecast, by Type Of Delivery System
6.3.4.3.2 Market size and forecast, by Application
6.3.4.4 Rest of LAMEA
6.3.4.4.1 Market size and forecast, by Type Of Delivery System
6.3.4.4.2 Market size and forecast, by Application
6.4 North America
6.4.1 Key trends and opportunities
6.4.2 North America Market size and forecast, by Type Of Delivery System
6.4.3 North America Market size and forecast, by Application
6.4.4 North America Market size and forecast, by country
6.4.4.1 U.S.
6.4.4.1.1 Market size and forecast, by Type Of Delivery System
6.4.4.1.2 Market size and forecast, by Application
6.4.4.2 Canada
6.4.4.2.1 Market size and forecast, by Type Of Delivery System
6.4.4.2.2 Market size and forecast, by Application
6.4.4.3 Mexico
6.4.4.3.1 Market size and forecast, by Type Of Delivery System
6.4.4.3.2 Market size and forecast, by Application
6.5 Europe
6.5.1 Key trends and opportunities
6.5.2 Europe Market size and forecast, by Type Of Delivery System
6.5.3 Europe Market size and forecast, by Application
6.5.4 Europe Market size and forecast, by country
6.5.4.1 Germany
6.5.4.1.1 Market size and forecast, by Type Of Delivery System
6.5.4.1.2 Market size and forecast, by Application
6.5.4.2 France
6.5.4.2.1 Market size and forecast, by Type Of Delivery System
6.5.4.2.2 Market size and forecast, by Application
6.5.4.3 U.K.
6.5.4.3.1 Market size and forecast, by Type Of Delivery System
6.5.4.3.2 Market size and forecast, by Application
6.5.4.4 Italy
6.5.4.4.1 Market size and forecast, by Type Of Delivery System
6.5.4.4.2 Market size and forecast, by Application
6.5.4.5 Spain
6.5.4.5.1 Market size and forecast, by Type Of Delivery System
6.5.4.5.2 Market size and forecast, by Application
6.5.4.6 Rest of Europe
6.5.4.6.1 Market size and forecast, by Type Of Delivery System
6.5.4.6.2 Market size and forecast, by Application
CHAPTER 7: COMPANY LANDSCAPE
7.1. Introduction
7.2. Top winning strategies
7.3. Product Mapping of Top 10 Player
7.4. Competitive Dashboard
7.5. Competitive Heatmap
7.6. Key developments
CHAPTER 8: COMPANY PROFILES
8.1 Viatris Inc.
8.1.1 Company overview
8.1.2 Company snapshot
8.1.3 Operating business segments
8.1.4 Product portfolio
8.1.5 Business performance
8.1.6 Key strategic moves and developments
8.2 Bayer AG
8.2.1 Company overview
8.2.2 Company snapshot
8.2.3 Operating business segments
8.2.4 Product portfolio
8.2.5 Business performance
8.2.6 Key strategic moves and developments
8.3 Boehringer Ingelheim GmbH
8.3.1 Company overview
8.3.2 Company snapshot
8.3.3 Operating business segments
8.3.4 Product portfolio
8.3.5 Business performance
8.3.6 Key strategic moves and developments
8.4 Endo International plc
8.4.1 Company overview
8.4.2 Company snapshot
8.4.3 Operating business segments
8.4.4 Product portfolio
8.4.5 Business performance
8.4.6 Key strategic moves and developments
8.5 GlaxoSmithKline plc
8.5.1 Company overview
8.5.2 Company snapshot
8.5.3 Operating business segments
8.5.4 Product portfolio
8.5.5 Business performance
8.5.6 Key strategic moves and developments
8.6 Johnson & Johnson
8.6.1 Company overview
8.6.2 Company snapshot
8.6.3 Operating business segments
8.6.4 Product portfolio
8.6.5 Business performance
8.6.6 Key strategic moves and developments
8.7 Novartis AG
8.7.1 Company overview
8.7.2 Company snapshot
8.7.3 Operating business segments
8.7.4 Product portfolio
8.7.5 Business performance
8.7.6 Key strategic moves and developments
8.8 Purdue Pharma L.P.
8.8.1 Company overview
8.8.2 Company snapshot
8.8.3 Operating business segments
8.8.4 Product portfolio
8.8.5 Business performance
8.8.6 Key strategic moves and developments
8.9 Altaris
8.9.1 Company overview
8.9.2 Company snapshot
8.9.3 Operating business segments
8.9.4 Product portfolio
8.9.5 Business performance
8.9.6 Key strategic moves and developments
8.10 Hisamitsu Pharmaceutical Co. Inc.
8.10.1 Company overview
8.10.2 Company snapshot
8.10.3 Operating business segments
8.10.4 Product portfolio
8.10.5 Business performance
8.10.6 Key strategic moves and developments


LIST OF TABLES
TABLE 1. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY TYPE OF DELIVERY SYSTEM, 2020-2030,($MILLION)
TABLE 2. TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET REVENUE, FOR PASSIVE, BY REGION , 2020-2030,($MILLION)
TABLE 3. TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET PASSIVE BY COUNTRY, 2020-2030,($MILLION)
TABLE 4. TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET REVENUE, FOR ACTIVE, BY REGION , 2020-2030,($MILLION)
TABLE 5. TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET ACTIVE BY COUNTRY, 2020-2030,($MILLION)
TABLE 6. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY APPLICATION, 2020-2030,($MILLION)
TABLE 7. TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET REVENUE, FOR ANALGESICS, BY REGION , 2020-2030,($MILLION)
TABLE 8. TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET ANALGESICS BY COUNTRY, 2020-2030,($MILLION)
TABLE 9. TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET REVENUE, FOR HORMONE REPLACEMENT THERAPIES, BY REGION , 2020-2030,($MILLION)
TABLE 10. TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET HORMONE REPLACEMENT THERAPIES BY COUNTRY, 2020-2030,($MILLION)
TABLE 11. TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET REVENUE, FOR HYPERTENSION, BY REGION , 2020-2030,($MILLION)
TABLE 12. TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET HYPERTENSION BY COUNTRY, 2020-2030,($MILLION)
TABLE 13. TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET REVENUE, FOR MOTION SICKNESS, BY REGION , 2020-2030,($MILLION)
TABLE 14. TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET MOTION SICKNESS BY COUNTRY, 2020-2030,($MILLION)
TABLE 15. TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET REVENUE, FOR SMOKING CESSATION, BY REGION , 2020-2030,($MILLION)
TABLE 16. TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET SMOKING CESSATION BY COUNTRY, 2020-2030,($MILLION)
TABLE 17. TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET REVENUE, FOR OTHERS, BY REGION , 2020-2030,($MILLION)
TABLE 18. TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET OTHERS BY COUNTRY, 2020-2030,($MILLION)
TABLE 19. TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY REGION, 2020-2030,($MILLION)
TABLE 20. ASIA-PACIFIC TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY TYPE OF DELIVERY SYSTEM, 2020-2030,($MILLION)
TABLE 21. ASIA-PACIFIC TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY APPLICATION, 2020-2030,($MILLION)
TABLE 22. ASIA-PACIFIC TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY COUNTRY, 2020-2030,($MILLION)
TABLE 23. JAPAN TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY TYPE OF DELIVERY SYSTEM 2020-2030,($MILLION)
TABLE 24. JAPAN TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY APPLICATION 2020-2030,($MILLION)
TABLE 25. CHINA TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY TYPE OF DELIVERY SYSTEM 2020-2030,($MILLION)
TABLE 26. CHINA TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY APPLICATION 2020-2030,($MILLION)
TABLE 27. INDIA TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY TYPE OF DELIVERY SYSTEM 2020-2030,($MILLION)
TABLE 28. INDIA TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY APPLICATION 2020-2030,($MILLION)
TABLE 29. AUSTRALIA TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY TYPE OF DELIVERY SYSTEM 2020-2030,($MILLION)
TABLE 30. AUSTRALIA TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY APPLICATION 2020-2030,($MILLION)
TABLE 31. SOUTH KOREA TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY TYPE OF DELIVERY SYSTEM 2020-2030,($MILLION)
TABLE 32. SOUTH KOREA TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY APPLICATION 2020-2030,($MILLION)
TABLE 33. REST OF ASIA-PACIFIC TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY TYPE OF DELIVERY SYSTEM 2020-2030,($MILLION)
TABLE 34. REST OF ASIA-PACIFIC TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY APPLICATION 2020-2030,($MILLION)
TABLE 35. LAMEA TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY TYPE OF DELIVERY SYSTEM, 2020-2030,($MILLION)
TABLE 36. LAMEA TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY APPLICATION, 2020-2030,($MILLION)
TABLE 37. LAMEA TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY COUNTRY, 2020-2030,($MILLION)
TABLE 38. BRAZIL TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY TYPE OF DELIVERY SYSTEM 2020-2030,($MILLION)
TABLE 39. BRAZIL TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY APPLICATION 2020-2030,($MILLION)
TABLE 40. SAUDI ARABIA TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY TYPE OF DELIVERY SYSTEM 2020-2030,($MILLION)
TABLE 41. SAUDI ARABIA TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY APPLICATION 2020-2030,($MILLION)
TABLE 42. SOUTH AFRICA TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY TYPE OF DELIVERY SYSTEM 2020-2030,($MILLION)
TABLE 43. SOUTH AFRICA TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY APPLICATION 2020-2030,($MILLION)
TABLE 44. REST OF LAMEA TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY TYPE OF DELIVERY SYSTEM 2020-2030,($MILLION)
TABLE 45. REST OF LAMEA TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY APPLICATION 2020-2030,($MILLION)
TABLE 46. NORTH AMERICA TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY TYPE OF DELIVERY SYSTEM, 2020-2030,($MILLION)
TABLE 47. NORTH AMERICA TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY APPLICATION, 2020-2030,($MILLION)
TABLE 48. NORTH AMERICA TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY COUNTRY, 2020-2030,($MILLION)
TABLE 49. U.S. TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY TYPE OF DELIVERY SYSTEM 2020-2030,($MILLION)
TABLE 50. U.S. TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY APPLICATION 2020-2030,($MILLION)
TABLE 51. CANADA TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY TYPE OF DELIVERY SYSTEM 2020-2030,($MILLION)
TABLE 52. CANADA TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY APPLICATION 2020-2030,($MILLION)
TABLE 53. MEXICO TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY TYPE OF DELIVERY SYSTEM 2020-2030,($MILLION)
TABLE 54. MEXICO TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY APPLICATION 2020-2030,($MILLION)
TABLE 55. EUROPE TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY TYPE OF DELIVERY SYSTEM, 2020-2030,($MILLION)
TABLE 56. EUROPE TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY APPLICATION, 2020-2030,($MILLION)
TABLE 57. EUROPE TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY COUNTRY, 2020-2030,($MILLION)
TABLE 58. GERMANY TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY TYPE OF DELIVERY SYSTEM 2020-2030,($MILLION)
TABLE 59. GERMANY TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY APPLICATION 2020-2030,($MILLION)
TABLE 60. FRANCE TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY TYPE OF DELIVERY SYSTEM 2020-2030,($MILLION)
TABLE 61. FRANCE TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY APPLICATION 2020-2030,($MILLION)
TABLE 62. U.K. TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY TYPE OF DELIVERY SYSTEM 2020-2030,($MILLION)
TABLE 63. U.K. TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY APPLICATION 2020-2030,($MILLION)
TABLE 64. ITALY TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY TYPE OF DELIVERY SYSTEM 2020-2030,($MILLION)
TABLE 65. ITALY TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY APPLICATION 2020-2030,($MILLION)
TABLE 66. SPAIN TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY TYPE OF DELIVERY SYSTEM 2020-2030,($MILLION)
TABLE 67. SPAIN TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY APPLICATION 2020-2030,($MILLION)
TABLE 68. REST OF EUROPE TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY TYPE OF DELIVERY SYSTEM 2020-2030,($MILLION)
TABLE 69. REST OF EUROPE TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY APPLICATION 2020-2030,($MILLION)
TABLE 70.VIATRIS INC.: COMPANY SNAPSHOT
TABLE 71.VIATRIS INC.: OPERATING SEGMENTS
TABLE 72.VIATRIS INC.: PRODUCT PORTFOLIO
TABLE 73.VIATRIS INC.: NET SALES,
TABLE 74.VIATRIS INC.: KEY STRATERGIES
TABLE 75.BAYER AG: COMPANY SNAPSHOT
TABLE 76.BAYER AG: OPERATING SEGMENTS
TABLE 77.BAYER AG: PRODUCT PORTFOLIO
TABLE 78.BAYER AG: NET SALES,
TABLE 79.BAYER AG: KEY STRATERGIES
TABLE 80.BOEHRINGER INGELHEIM GMBH: COMPANY SNAPSHOT
TABLE 81.BOEHRINGER INGELHEIM GMBH: OPERATING SEGMENTS
TABLE 82.BOEHRINGER INGELHEIM GMBH: PRODUCT PORTFOLIO
TABLE 83.BOEHRINGER INGELHEIM GMBH: NET SALES,
TABLE 84.BOEHRINGER INGELHEIM GMBH: KEY STRATERGIES
TABLE 85.ENDO INTERNATIONAL PLC: COMPANY SNAPSHOT
TABLE 86.ENDO INTERNATIONAL PLC: OPERATING SEGMENTS
TABLE 87.ENDO INTERNATIONAL PLC: PRODUCT PORTFOLIO
TABLE 88.ENDO INTERNATIONAL PLC: NET SALES,
TABLE 89.ENDO INTERNATIONAL PLC: KEY STRATERGIES
TABLE 90.GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
TABLE 91.GLAXOSMITHKLINE PLC: OPERATING SEGMENTS
TABLE 92.GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
TABLE 93.GLAXOSMITHKLINE PLC: NET SALES,
TABLE 94.GLAXOSMITHKLINE PLC: KEY STRATERGIES
TABLE 95.JOHNSON & JOHNSON: COMPANY SNAPSHOT
TABLE 96.JOHNSON & JOHNSON: OPERATING SEGMENTS
TABLE 97.JOHNSON & JOHNSON: PRODUCT PORTFOLIO
TABLE 98.JOHNSON & JOHNSON: NET SALES,
TABLE 99.JOHNSON & JOHNSON: KEY STRATERGIES
TABLE 100.NOVARTIS AG: COMPANY SNAPSHOT
TABLE 101.NOVARTIS AG: OPERATING SEGMENTS
TABLE 102.NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 103.NOVARTIS AG: NET SALES,
TABLE 104.NOVARTIS AG: KEY STRATERGIES
TABLE 105.PURDUE PHARMA L.P.: COMPANY SNAPSHOT
TABLE 106.PURDUE PHARMA L.P.: OPERATING SEGMENTS
TABLE 107.PURDUE PHARMA L.P.: PRODUCT PORTFOLIO
TABLE 108.PURDUE PHARMA L.P.: NET SALES,
TABLE 109.PURDUE PHARMA L.P.: KEY STRATERGIES
TABLE 110.ALTARIS: COMPANY SNAPSHOT
TABLE 111.ALTARIS: OPERATING SEGMENTS
TABLE 112.ALTARIS: PRODUCT PORTFOLIO
TABLE 113.ALTARIS: NET SALES,
TABLE 114.ALTARIS: KEY STRATERGIES
TABLE 115.HISAMITSU PHARMACEUTICAL CO. INC.: COMPANY SNAPSHOT
TABLE 116.HISAMITSU PHARMACEUTICAL CO. INC.: OPERATING SEGMENTS
TABLE 117.HISAMITSU PHARMACEUTICAL CO. INC.: PRODUCT PORTFOLIO
TABLE 118.HISAMITSU PHARMACEUTICAL CO. INC.: NET SALES,
TABLE 119.HISAMITSU PHARMACEUTICAL CO. INC.: KEY STRATERGIES


LIST OF FIGURES
FIGURE 1.TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET SEGMENTATION
FIGURE 2.TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET,2020-2030
FIGURE 3.TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET,2020-2030
FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
FIGURE 5.PORTER FIVE-1
FIGURE 6.PORTER FIVE-2
FIGURE 7.PORTER FIVE-3
FIGURE 8.PORTER FIVE-4
FIGURE 9.PORTER FIVE-5
FIGURE 10.TOP PLAYER POSITIONING
FIGURE 11.TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
FIGURE 11.TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET,BY TYPE OF DELIVERY SYSTEM,2020(%)
FIGURE 12.COMPARATIVE SHARE ANALYSIS OF PASSIVE TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET,2020-2030(%)
FIGURE 13.COMPARATIVE SHARE ANALYSIS OF ACTIVE TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET,2020-2030(%)
FIGURE 14.TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET,BY APPLICATION,2020(%)
FIGURE 15.COMPARATIVE SHARE ANALYSIS OF ANALGESICS TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET,2020-2030(%)
FIGURE 16.COMPARATIVE SHARE ANALYSIS OF HORMONE REPLACEMENT THERAPIES TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET,2020-2030(%)
FIGURE 17.COMPARATIVE SHARE ANALYSIS OF HYPERTENSION TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET,2020-2030(%)
FIGURE 18.COMPARATIVE SHARE ANALYSIS OF MOTION SICKNESS TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET,2020-2030(%)
FIGURE 19.COMPARATIVE SHARE ANALYSIS OF SMOKING CESSATION TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET,2020-2030(%)
FIGURE 20.COMPARATIVE SHARE ANALYSIS OF OTHERS TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET,2020-2030(%)
FIGURE 21.TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY REGION,2020
FIGURE 22.JAPAN TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET,2020-2030($MILLION)
FIGURE 23.CHINA TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET,2020-2030($MILLION)
FIGURE 24.INDIA TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET,2020-2030($MILLION)
FIGURE 25.AUSTRALIA TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET,2020-2030($MILLION)
FIGURE 26.SOUTH KOREA TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET,2020-2030($MILLION)
FIGURE 27.REST OF ASIA-PACIFIC TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET,2020-2030($MILLION)
FIGURE 28.BRAZIL TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET,2020-2030($MILLION)
FIGURE 29.SAUDI ARABIA TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET,2020-2030($MILLION)
FIGURE 30.SOUTH AFRICA TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET,2020-2030($MILLION)
FIGURE 31.REST OF LAMEA TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET,2020-2030($MILLION)
FIGURE 32.U.S. TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET,2020-2030($MILLION)
FIGURE 33.CANADA TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET,2020-2030($MILLION)
FIGURE 34.MEXICO TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET,2020-2030($MILLION)
FIGURE 35.GERMANY TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET,2020-2030($MILLION)
FIGURE 36.FRANCE TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET,2020-2030($MILLION)
FIGURE 37.U.K. TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET,2020-2030($MILLION)
FIGURE 38.ITALY TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET,2020-2030($MILLION)
FIGURE 39.SPAIN TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET,2020-2030($MILLION)
FIGURE 40.REST OF EUROPE TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET,2020-2030($MILLION)
FIGURE 41. TOP WINNING STRATEGIES, BY YEAR
FIGURE 42. TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 43. TOP WINNING STRATEGIES, BY COMPANY
FIGURE 44.PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 45.COMPETITIVE DASHBOARD
FIGURE 46.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
FIGURE 47.VIATRIS INC..: NET SALES ,($MILLION)
FIGURE 48.BAYER AG.: NET SALES ,($MILLION)
FIGURE 49.BOEHRINGER INGELHEIM GMBH.: NET SALES ,($MILLION)
FIGURE 50.ENDO INTERNATIONAL PLC.: NET SALES ,($MILLION)
FIGURE 51.GLAXOSMITHKLINE PLC.: NET SALES ,($MILLION)
FIGURE 52.JOHNSON & JOHNSON.: NET SALES ,($MILLION)
FIGURE 53.NOVARTIS AG.: NET SALES ,($MILLION)
FIGURE 54.PURDUE PHARMA L.P..: NET SALES ,($MILLION)
FIGURE 55.ALTARIS.: NET SALES ,($MILLION)
FIGURE 56.HISAMITSU PHARMACEUTICAL CO. INC..: NET SALES ,($MILLION)